Skip to main content
SpringerLink
Log in

Schmerztherapie und Symptomkontrolle in der Palliativmedizin

  • Chapter
Palliativmedizin

Zusammenfassung

In Deutschland erkranken jährlich ca. 400.000 Menschen neu an einer Tumorerkrankung [8]. Die Mehrzahl der Patienten wird im Verlauf der Erkrankung an Schmerzen unterschiedlicher Intensität leiden. In der Frühphase einer Tumorerkrankung berichten etwa 20–50%, im fortgeschrittenen Stadium etwa 55–95% der Patienten über Schmerzen [16, 209].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adamietz et al. (1999) Leitlinien zur Tumorschmerztherapie. Erstellt im Auftrag der Deutschen Interdisziplinären Vereinigung für Schmerztherapie (DIVS). Tumordiagn. u. Ther. 20: 105–129

    Google Scholar 

  2. Ahmedzai S (1998) Palliation of respiratory symptoms. In: Doyle D, Hanks GWC, Mac-Donald N (eds) Oxford Textbook of Palliative Medicine, 2nd edition. Oxford Univ Press, Oxford New York, pp 583–616

    Google Scholar 

  3. Ajemian SG (1993) Palliative management of dyspnea. J Palliat Care 7/3: 44–45

    Google Scholar 

  4. Allan SG (1993) Nausea and vomiting. In: Doyle D, Hanks GWC, MacDonald N (eds) Oxford Textbook of Palliative Medicine. Oxford Univ Press, Oxford New York, pp 282–290

    Google Scholar 

  5. American Pain Society (1989) Principles of analgesic use in the treatment of acute pain and chronic cancer pain. A concise guide to medical practice, 2nd edn. American Pain Society, Skokie/IL

    Google Scholar 

  6. Anderson R, Saijers JH, Abram S, Schlicht C (2001) Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 21: 397–406

    PubMed  CAS  Google Scholar 

  7. Angst MS, Bührer M, Lötsch J (2000) Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology 92: 1473–1476

    PubMed  CAS  Google Scholar 

  8. Arbeitsgemeinschaft Bevölkerungsbezogenes Krebsregister in Deutschland in Zusammenarbeit mit dem Robert-Koch-Institut (2004): Krebs in Deutschland — Häufigkeiten und Trends, 4. Auflage

    Google Scholar 

  9. Arzneimittelkommission der Deutschen Ärzteschaft (2007) Arzneiverordnung in der Praxis, Band 34 (Sonderheft 1: Therapieempfehlungen)

    Google Scholar 

  10. Back IN (1992) Terminal restlessness in patients with advanced malignant disease. Palliat Med 6: 293–298

    Google Scholar 

  11. Baron R, Jänig W (2001) Neuropathische Schmerzen. In:Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 65–87

    Google Scholar 

  12. Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ (2007) Measurement of breathlessness in advanced disease: A systematic review. Respiratory Medicine 101: 399–410

    PubMed  CAS  Google Scholar 

  13. Bausewein C, Remi C, Twycross R, Wilcock A (2005) Arzneimitteltherapie in der Palliativmedizin. Urban&Fischer, München Jena

    Google Scholar 

  14. Boas RA, Holford NHG, Villinger JW (1985) Clinical pharmacology of opiate analgesia. Adv Pain Res Ther 9: 695–708

    Google Scholar 

  15. Böger RH, Schmidt G (2002) Analgetika. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2002. Springer, Berlin Heidelberg New York Tokio, 89–103

    Google Scholar 

  16. Bonica JJ, Loeser JD, Chapman CR, Fordyce WE (1990) The management of pain. Lea & Febinger, Philadelphia London

    Google Scholar 

  17. Boston-Studie (1986) Risk of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. JAMA 256: 1749–1757

    Google Scholar 

  18. Bourke DL, Warley A (1989) The steady state and breathing methods compared during morphine administration in humans. J Physiol 419, 509–517

    PubMed  CAS  Google Scholar 

  19. Bozetti et al. (1996) Guidelines on artificial nutrition versus hydration in terminal cancer patients. Nutrition 12/3: 163–167

    Google Scholar 

  20. Brennscheidt U, Seiler KU, Thomann P (2000) Pharmacokinetics of nortilidine and naloxone after administration of tilidine/naloxone solution and of tilidine/naloxone sustained release tablets. Arzneim.-Forsch/Drug Res 50: 1015–1022

    CAS  Google Scholar 

  21. Bruera E, Brenneis C, Paterson AH, MacDonald RM (1989) Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 4: 3

    PubMed  CAS  Google Scholar 

  22. Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald RM (1987) Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Report 76: 17

    Google Scholar 

  23. Bruera E, Pereira J, Watanabe SE et al. (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78: 852–857

    PubMed  CAS  Google Scholar 

  24. Bruera E, Sweeney C (2002) Methadone use in cancer patients with pain: A review. J Pall Med 5: 127–138

    Google Scholar 

  25. Brune K, Hinz B (2001) Nichtopioidanalgetika (antipyretische Analgetika und andere). In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 233–253

    Google Scholar 

  26. Brune K, Kalden J, Zacher J, Zeilhofer HU (2000) Selektive Inhibitoren der Zyklooxygenase. 2. Evolution oder Revolution? Dtsch Ärztebl 97: B1540–1547

    Google Scholar 

  27. Bullingham R, McQuay H, Porter E, Weir L (1982) Sublingual buprenorphine used postoperatively: 10 hour plasma drug concentration analysis. Br J Clin Pharmacol 13: 665

    PubMed  CAS  Google Scholar 

  28. Campbell JN (1996) Pain 1996 — An updated review. IASP Press, Seattle

    Google Scholar 

  29. Caraceni A, Zecca E, Martini C, De Conno F (1999) Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17: 441–445

    PubMed  CAS  Google Scholar 

  30. Chandler A, Williams JE (2000) Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hosipital. J Pain Symptom Manage 20: 82–86

    PubMed  CAS  Google Scholar 

  31. Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ, Sperber AD (2006) Gender, age, society, culture, and the patient’s perspective in the functional gastrointestinal disorders. Gastroenterology 130(5): 1435–1346

    PubMed  Google Scholar 

  32. Cherny N, Ripamonti C, Pereira J et al. (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19: 2542–2554

    PubMed  CAS  Google Scholar 

  33. Cherny NI (1996) The medical treatment of pain in the terminal stages of cancer and other illnesses. In: Campbell JN (ed) Pain 1996 — An updated review. IASP Press, Seattle, pp 469–484

    Google Scholar 

  34. Cherny NI, Portenoy RK, Raber M, Zenz M (1994) Medikamentöse Therapie von Tumorschmerzen, Teil I: Eigenschaften von Nichtopioiden und Opioiden. Der Schmerz 8: 195–209

    PubMed  CAS  Google Scholar 

  35. Cherny NI, Portenoy RK, Raber M, Zenz M (1994) Medikamentöse Therapie von Tumorschmerzen, Teil II: Anwendung von Opioiden. Der Schmerz 9: 3–10

    Google Scholar 

  36. Cherny NI, Portenoy RK, Raber M, Zenz M (1994) Medikamentöse Therapie von Tumorschmerzen, Teil III: Adjuvanzien. Der Schmerz 9: 55–69

    Google Scholar 

  37. CIOMS (Council for International Organizations of Medical Sciences) (1998) Benefit-risk balance for marketed drugs: evaluating safety signals. Report of CIOMS Working Group IV. Geneva, 117–114

    Google Scholar 

  38. Clemens KE, Klaschik E (2007) Symptomatische Therapie der Dyspnoe bei Patienten in der Palliativmedizin: Sauerstoff-Insufflation versus Opioidapplikation. Dtsch Med Wochenschr 132(38): 1939–1943

    PubMed  CAS  Google Scholar 

  39. Clemens KE, Klaschik E (2007) Übelkeit, Erbrechen und Obstipation in der palliativen Situation. Deutsches Ärzteblatt 5: 269–277

    Google Scholar 

  40. Clemens KE, Quednau I, Klaschik E (2008) Use of oxygen and opioids in the palliation of dyspnoea in hypoxic and non-hypoxic palliative care patients: a prospective study. Support Care Cancer 2008 Aug 22. [Epub ahead of print]

    Google Scholar 

  41. Collins SL, Faura CC, Moore A, McQuay HJ (1998) Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 16: 388–401

    PubMed  CAS  Google Scholar 

  42. Coluzzi PH, Schwartzberg L, Conroy Jr JD et al. (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSRI). Pain 91: 123–130

    PubMed  CAS  Google Scholar 

  43. Comroe JH, Forster RE, Dubois AB, Briscoe WA, Carlsen E (1968) Die Lunge. Schattauer Stuttgart

    Google Scholar 

  44. Cools HJM, Berkhout AMM, De Bock GH (1996) Subcutaneous morphine infusion by syringe driver for terminally ill patients. Age Ageing 25: 206–208

    PubMed  CAS  Google Scholar 

  45. Coyle H, Ingham J (1996) Pain management in the imminently dying — Goals of care, ethical issues, and the role of sedation: An illustrative case. In: Campbell JN (ed) Pain 1996 — An updated review. IASP Press, Seattle, pp 567–657

    Google Scholar 

  46. Coyle N, Adelhardt J, Foley KM, Portenoy RK (1990) Character of terminal illness in the advanced cancer patient. J Pain Symptom Manage 5: 83

    PubMed  CAS  Google Scholar 

  47. De Sio JM, Bacon DR, Peer G, Lema MJ (1993) Intravenous abuse of transdermal fentanyl therapy in a chronic pain patient. Anesthesiology 79: 1139–1141

    Google Scholar 

  48. De Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10: 378–384

    PubMed  Google Scholar 

  49. Dejgard A, Petersen P, Kastrup J (1988) Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1: 9–11

    PubMed  CAS  Google Scholar 

  50. Deutsche Krebsgesellschaft(2002) Kurzgefasste Interdisiplinäre Leitlinien. 3. Auflage, 2002

    Google Scholar 

  51. Devulder J, Ghys L, Dhondt W, Rholly G (1994) Spinal analgesia in terminal care: Risk versus benefit. J Pain Symptom Manage 9/2: 75–81

    Google Scholar 

  52. Donner B, Strumpf M, Dertwinkel R, Zenz M (1997) Neue Alternative in der Tumortherapie. Richtige Anwendung von Fentanyl TTS entscheidend. Dtsch Ärztebl 94/10: A 598–599

    Google Scholar 

  53. Dooley M, Balfour JA (1999) Ibandronate. Drugs 57: 101–108

    PubMed  CAS  Google Scholar 

  54. Drechsler S, Bauer R (1995) 5-HT-3-Rezeptorantagonisten. Der Weg zum therapeutischen Fortschritt in der supportiven Tumortherapie. Arzneimitteltherapie 8: 224–235

    Google Scholar 

  55. Edinboro LE, Poklis A, Trautman D, Lowry S, Backer R, Harvey CH (1997) Fatal fentanyl intoxication following excessive transdermal application. J Forensic Sci 42: 741–743

    PubMed  CAS  Google Scholar 

  56. Ellershaw JE, Suttcliffe JM, Saunders CM (1995) Dehydration and the dying patient. J Pain Symptom Manage 10/3: 192–197

    Google Scholar 

  57. Eisner F, Radbruch L, Sabatowski R et al. (1999) Opioidwechsel auf transdermales Fentanyl im klinischen Alltag. Schmerz 13: 273–278

    Google Scholar 

  58. Expert Working Group of the Research Network of the European Association for Palliative Care: Hanks GW, deConno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Rpiamonti C, Radbruch L, Twycross R et al. (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587–593

    PubMed  CAS  Google Scholar 

  59. Fainsinger RL, Bruera E (1994) The management of dehydration in terminally ill patients. Palliat Care 10: 55–59

    CAS  Google Scholar 

  60. Fainsinger RL, Spachynski K, Hanson J, Bruera E (1994) Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 9/1:12–18

    Google Scholar 

  61. Fainsinger RL; Miller MJ, Bruera E (1991) Symptom control during the last weeks of life on a palliative care unit. J Palliat Care 7/1: 5–11

    Google Scholar 

  62. Farncombe M, Chater S (1993) Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. J Pain Symptom Manage 8/4: 221–225

    Google Scholar 

  63. Foley KM (1985) The treatment of cancer pain. N Engl J Med 313: 84

    PubMed  CAS  Google Scholar 

  64. Foley KM (1989): Controversies in cancer pain: medical perspective. Cancer 63: 2257

    PubMed  CAS  Google Scholar 

  65. Foley KM (1993) Opioid analgesics in clinical pain management. In: Herz A (ed) Opioids. Handbook of experimental pharmacology, vol 104/II. Springer, Berlin Heidelberg New York Tokyo, pp 697–743

    Google Scholar 

  66. Foley KM, Inturrisi CE (1987) Analgesic drug therapy in cancer pain: Principles and practice. Med Clin North Am 71: 107

    Google Scholar 

  67. Foley KM, Inturrisi CE (1989) Pharmacological approaches to cancer pain. In: Foley KM, Payne RM (eds) Current therapy of pain. Decker, Toronto, pp 303–331

    Google Scholar 

  68. Forman B, Portenoy RK, Yanagihara RH, Hunt WC, Kush R, Shepard K (1992) Elderly cancer patients with pain: response to oral morphine (MS) dose, pain and toxicity. J Am Geriatr Soc 40/10: SA 26

    Google Scholar 

  69. Freynhagen R, Zenz M, Strumpf M (1994) WHO Stufe II — Klinische Realität oder didaktisches Instrument. Der Schmerz 8: 210–215

    PubMed  CAS  Google Scholar 

  70. Frolich M, Gianotti A, Modell JH (2002) Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 93: 647–648

    Google Scholar 

  71. Füsgen I, Wanitschke R (2001) Obstipationsmanual. Diagnostik, Therapie und Rehabilitation. Schriftenreihe Geriatrie. Der ältere Patient in Praxis und Klinik. Vincentz Verlag, Hannover

    Google Scholar 

  72. Gestin Y, Vainio A, Pérugier AM (1997) Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anaesthesiol Scand 41: 12–17

    PubMed  CAS  Google Scholar 

  73. Goh CR (1996) Routes of opioid administration: The role of sublingual/buccal, transdermal and parenteral infusion therapy. In: Campbell JN (ed) Pain 1996 —An updated review. IASP Press, Seattle

    Google Scholar 

  74. Gorman DJ (1991) Opioid analgesics in the management of pain in patients with cancer: An update. Palliat Med 5: 277–329

    Google Scholar 

  75. Grand S, Zech D (1992) Aktuelle Strategien in der Behandlung von Tumorschmerzen. Med Klinik 87/4: 198–206

    Google Scholar 

  76. Grond S, Zech D, Dahlmann H, Schug SA, Stobbe B, Lehmann KA (1990) Überweisungsgrund „therapieresistente“ Tumorschmerzen. Schmerz 4: 193–200

    PubMed  Google Scholar 

  77. Grond S, Zech D, Meuser T, Radbruch L, Kasper M, Lehmann KA (1992) Prävalenz und Charakteristik neuropathischer Schmerzen bei malignen Erkrankungen. Der Schmerz 6: 99–104

    PubMed  Google Scholar 

  78. Grond S, Zech D, Schug SA, Lynch J, Lehmann KA (1991) Validation of World Health Organisation Guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 6/7: 411–413

    Google Scholar 

  79. Hackenthal E (1999) Therapie mit Analgetika/nicht steroidalen Antirheumatika. In: Platt D, Mutschier E (Hrsg) Pharmakotherapie im Alter. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 377–401

    Google Scholar 

  80. Hagen N, Thrilwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC (1995) Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 35: 37–44

    PubMed  CAS  Google Scholar 

  81. Hagen NA, Babul N (1997) Comparative clinical efficacy and safety of a novel controlledreleased oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79: 1428–1437

    PubMed  CAS  Google Scholar 

  82. Hamunen K, Olkola KT, Maunuksela EL (1993) Comparison of the ventilatory effects of morphine and buprenorphine in children. Acta Anaesthesiol Scand 37: 449–453

    PubMed  CAS  Google Scholar 

  83. Hankemeier U, Schüle-Hein K, Krizanits (Hrsg) (2001) Tumorschmerztherapie, 2., völlig neu bearbeitete und erweiterte Auflage. Springer Verlag, Berlin

    Google Scholar 

  84. Hanks GW (1996) Principles of system opioid pharmacotherapy. In: Campbell JN (ed) Pain 1996 — An updated review. IASP Press, Seattle, pp 219–238

    Google Scholar 

  85. Hanks GW, Justins DM (1992) Cancer pain: management. Lancet 39: 1031–1036

    Google Scholar 

  86. Hanks GW, Twycross RG, Lloyd JW (1981) Unexpected complication of successful nerve block. Anaesthesia 36: 37–39

    PubMed  CAS  Google Scholar 

  87. Hardwick WR Jr, King WD, Palmisano PA (1997) Respiratory depression in a child unintentionally exposed to transdermal fentanyl patch. South Med J 90: 9962–9964

    Google Scholar 

  88. Heaton KW, O’Donnell LJ, Braddon FE, Mountford RA, Hughes RO, Cripps PJ (1992) Symptomes of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 102: 1962–1967

    PubMed  CAS  Google Scholar 

  89. Heidemann E (1999) Tumorpatienten in Deutschland: Was wissen wir über Schmerzprävalenzen? Schmerz 13: 249–252

    PubMed  CAS  Google Scholar 

  90. Herz A, Stein C (1992) Opioide vermitteln antinozizeptive Wirkungen in der entzündeten Pfote von Ratten. Der Schmerz 5: 158–159

    Google Scholar 

  91. Heyse-Moore LH, Poss V, Mullee MA (1991) How much of a problem is dyspnoea in advanced cancer? Palliat Med 5: 20–26

    Google Scholar 

  92. Hildebrandt J (1994) Therapie chronischer Schmerzen. Jungjohann Verlagsgesellschaft, Neckarsulm

    Google Scholar 

  93. Hinz B, Brune K (1999) Spezifische COX-2-Inbitoren: Perspektiven einer Therapie mit neuen analgetischen und antiinflammatorischen Wirkstoffen. Wien Klein Wochenschr 111: 103–112

    CAS  Google Scholar 

  94. Hinz B, Brune K (2002) Pharmakologie: Analgetika. In: Beck H, Martin E, Motsch J, Schulteam Esch J (Hrsg)1 Schmerztherapie. Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie, Band 42. Thieme, Stuttgart New York, S. 103–117

    Google Scholar 

  95. Hogan Q, Haddox JD, Abram S, Weissmann D, Taylor ML, Janjan N (1991) Epidural opiates and local anesthetics fort he management of cancer pain. Pain 46: 271–279

    PubMed  CAS  Google Scholar 

  96. Illes P, Jurna I, Kaever V, Resch K (1998) Analgetika und Antiphlogistika. Schmerzbekämpfung und antirheumatischeTherapie. In: Forth W, Henschler D, Rummel W, Starke K (Hrsg) Allgemeine und spezielle Pharmakologie und Toxikologie. 7., völlig neu bearbeitete Aufl. Spektrum Akademischer Verlag, Heidelberg Berlin, 201–225

    Google Scholar 

  97. Indelicato RA, Portenoy RK (2002) Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20: 348–352

    PubMed  Google Scholar 

  98. International Narcotics Control Board (2002) Consumption of principal narcotic drugs (2001) Narcotic Drugs. Estimated world requirements for 2002, statistics for 2000. United Nations, New York

    Google Scholar 

  99. International Narcotics Control Board (2007) Consumption of principal narcotic drugs. Narcotic Drugs. Estimated world requirements 2008, statistics for 2006. United Nations, New York

    Google Scholar 

  100. Jage J (1995) Medikamente gegen Krebsschmerzen. Chapman & Hall, London Weinheim

    Google Scholar 

  101. Jage J (2003) Medikamente gegen Krebsschmerzen. 4., völlig neu bearbeitete Auflage. Thieme, Stuttgart

    Google Scholar 

  102. Jage J, Jurna I (2001) Opioidanalgetika. In:Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 255–280

    Google Scholar 

  103. Jensen TS (2002) Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 6(Suppl A): 61–68

    PubMed  CAS  Google Scholar 

  104. Jurna I (1997) Opioid and nonopioid agents: some aspects of central (spinal) and peripheral actions. Pain Rev 4: 205–224

    CAS  Google Scholar 

  105. Jurna I, Baldauf J (1993) Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. Der Schmerz 7: 314

    PubMed  CAS  Google Scholar 

  106. Kaiko RF (1997) Pharmacokinetics and pharmacodynamics of controlled-release opioids. Acta Anaesthesiol Scand 41: 166–174

    PubMed  CAS  Google Scholar 

  107. Kalso E, Vainio A (1990) Morphine and oxycodone in the management of cancer pain. Clin Pharmacol Ther 47: 639–646

    PubMed  CAS  Google Scholar 

  108. Karavelis A, Foroglou G, Selviaridis P, Fountzilas G (1996) Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery 39: 57–62

    PubMed  CAS  Google Scholar 

  109. Kaufmann PN, Krevsky B, Malmud LS, Maurer AH, Sommers MB, Siegel JA, Fisher RS (1988) Role of opioid receptors in the regulation of colonic transit. Gastroenterology 94: 1351

    Google Scholar 

  110. Klaschik E (2003) Symptome in der Palliativmedizin: Obstipation. Schlütersche, Hannover

    Google Scholar 

  111. Klaschik E, Clemens KE (2005) Opioide in der Tumorschmerztherapie — Wirksamkeit und Nebenwirkungen. Schmerz 19: 395–403

    PubMed  CAS  Google Scholar 

  112. Klockgether-Radke AP, Gaus P, Neumann P (2002) Opioidintoxikation durch transdermales Fentanyl. Der Änaesthesist 51:269–271

    PubMed  CAS  Google Scholar 

  113. Klockgether-Radkke A, Hildebrandt J (1997) Opioidintoxikation. Unsachgemäße Anwendung von transdermalem Fentanyl. Anaesthesist 46: 428–429

    Google Scholar 

  114. Kramer C, Tawney H (1998) A fatal overdose of transdermally administered fentanyl. J Am Osteopath Assoc 98: 385–386

    PubMed  CAS  Google Scholar 

  115. Krames ES (1993) Intrathecal infusional therapies for intractable pain: patient management guidelines. J Pain Sympt Manage 8: 36–46

    CAS  Google Scholar 

  116. Larsen B, Otto H, Dorscheid E, Larsen R (1999) Aufmerksamkeitsbelastung und Reaktionszeiten unter Opioiddauertherapie. Anaesthesist 48: 613–624

    PubMed  CAS  Google Scholar 

  117. Lawlor P, Turner K, Hanson J, Bruera E (1997) Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 72: 79–85

    PubMed  CAS  Google Scholar 

  118. Lee MA, Leng MEF, Tiernan EJJ (2001) Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 15: 26–34

    PubMed  CAS  Google Scholar 

  119. Lehmann KA (1994) Der postoperative Schmerz. Springer, Berlin Heidelberg New York Tokio

    Google Scholar 

  120. Lehmann KA (Hrsg) (2002) Analgetische Therapie mit Opioiden. UNI-MED, Bremen

    Google Scholar 

  121. Lehmann KA, Zech D (1993) Morphine-6-glucuronide, a pharmacologically active morphine metabolite. Eur J Pain 14: 28–35

    Google Scholar 

  122. Lema MJ (1993) Cancer pain management: An overview of current therapeutic regimens. Semin Anesth XII/2:109–111

    Google Scholar 

  123. Leutner V (1990) Schlaf, Schlafstörungen, Schlafmittel. Editiones Roches, Basel

    Google Scholar 

  124. Lichter I (1993) Results of antiemetic management in terminal illness. J Palliat Care 9/2: 19–21

    Google Scholar 

  125. Lichter I (1994) Accelerated titration of morphine for rapid relief of cancer pain. NZ Med J 107: 488–490

    CAS  Google Scholar 

  126. Lichtor JL, Sevarino FB, Joshi GP, Busch MA, Nordbrock E, Ginsberg B (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anest Analg 89: 732–738

    CAS  Google Scholar 

  127. Likar R, Sittl R (2002) Praxis der transdermalen Schmerztherapie. UNI-MED, Bremen

    Google Scholar 

  128. Lindena G, Arnau H, Liefhold J (1998) Hydromorphon — pharmakologische Eigenschaften und therapeutische Wirksamkeit. Schmerz 12: 195–204

    PubMed  CAS  Google Scholar 

  129. Lindena G, Müller S, Zenz T (1994) Opioidverschreibung durch niedergelassene Ärzte. Der Schmerz 8: 228–234

    PubMed  Google Scholar 

  130. Lloyd JW, Barnard JDW, Glynn CJ (1976) Cryoanalgesia: a new approach to pain relief. Lancet II: 932–934

    Google Scholar 

  131. Locke GR III. (1996) The epidemiology of functional gastrointestinal disorders in North America. Gastroenterol Clin North Am 25: 1–19

    PubMed  Google Scholar 

  132. Loick G, Radbruch L, Petzke F, Lehmann KA (1996) Tumorschmerztherapie bei geriatrischen Patienten im Vergleich mit jüngeren Patienten. Der Schmerz 10(Suppl 1): 58

    Google Scholar 

  133. Lorenz J, Baumgärtner U, Zander AR, Bromm B (1996) Differenzierung von schmerz-und morphinbedingter Beeinträchtigung kognitiver Leistungen und subjektiver Befindlichkeit bei Knochenmarktransplantationspatienten. Der Schmerz 10: 80–88

    PubMed  CAS  Google Scholar 

  134. Lorenz J, Beck H, Bromm B (1997) Cognitive performance, mood and experimental pain before and during morphin-induced analgesia in patients with chronic non-malignant pain. Pain 73: 189–195

    Google Scholar 

  135. Lötsch J, Geisslinger G, Tegeder I (2001) Opioide bei Leberoder Nierenfunktionsstörung. In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 329–334

    Google Scholar 

  136. Lynn AN, Slattery JT (1987) Morphine pharmacokinetics in early infancy. Anesthesiology 66: 136–139

    PubMed  CAS  Google Scholar 

  137. MacDonald FC, Gough KJ, Nicoll RAG, Dow RJ (1989) Psychomotor effects of ketolorac in comparison with buprenorphine and diclophenac. Br J Pharmacol 27: 453–459

    CAS  Google Scholar 

  138. Maier C, Senne I (2001) Calcitonin und Bisphosphonate. In: Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 309–321

    Google Scholar 

  139. Maloney CM, Kesner RK, Klein G, Bockenstette J (1989) The rectal administration of MS contin: Clinical implications of use in end stage cancer. Am J Hospice Care 6/4: 34–35

    Google Scholar 

  140. Mancini I, Lossignol DA, Body JJ (2000) Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 12: 308–313

    PubMed  CAS  Google Scholar 

  141. Mao J, Chen LL (2000) Gabapentin in pain management. Anesth Analg 91: 680–687

    PubMed  CAS  Google Scholar 

  142. Mao J, Price D, Mayer DH (1995) Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 662: 259–274

    Google Scholar 

  143. Marquardt KA, Tharrat RS (1994) Inhalation abuse of fentanyl patch. J Toxikol Clin Toxikol 32: 75–78

    CAS  Google Scholar 

  144. Mather LE (2001) Trends in the pharmacology of opioids: implications for the pharmacotherapy of pain. Eur J Pain 5(Suppl A): 49–57

    PubMed  CAS  Google Scholar 

  145. Maydell R von, Voltz R (1996) Palliativmedizin: Neurologie und Psychiatrie. Deutsche Gesellschaft für Palliativmedizin, München

    Google Scholar 

  146. McQuay HJ, Carroll D, Faura CC, Gavagghan DJ, Hand CW, Moore RA (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48: 236

    PubMed  CAS  Google Scholar 

  147. Melzack R, Mount BM, Gordon JM (1979) The Brompton mixture versus morphine solution given orally: effects on pain. Can Med Assoc J 120: 435–439

    PubMed  CAS  Google Scholar 

  148. Mercadante S (1999a) Opioid rotation for cancer pain. Rational and clinical aspects. Cancer 96: 1856–1866

    Google Scholar 

  149. Mercadante S (1999b) Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 79: 1–13

    PubMed  CAS  Google Scholar 

  150. Mercadante S, Portenoy RK (2001a) Opioid poorly-responsive cancer pain. Part 1. Clinical considerations. J Pain Symptom Manage 21: 144–150

    PubMed  CAS  Google Scholar 

  151. Mercadante S, Portenoy RK (2001b) Opioid poorly-responsive cancer pain. Part 2. Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 21: 255–264

    PubMed  CAS  Google Scholar 

  152. Mercadante S, Portenoy RK (2001c) Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 21: 338–354

    PubMed  CAS  Google Scholar 

  153. Meuser T, Pietruck C, Radbruch L et al. (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93: 247–257

    PubMed  CAS  Google Scholar 

  154. Müller H (2001) Spinale Opioidanalgetika. ln:Zenz M, Jurna I (Hrsg) Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 441–456

    Google Scholar 

  155. Müller-Busch HC (2004) Sterbende sedieren? Z Palliativmed 5: 107–112

    Google Scholar 

  156. Müller-Lissner S (1992) Nebenwirkungen von Laxantien. Z Gastroenterol 30: 418–427

    PubMed  Google Scholar 

  157. Munzinger H, Horstkotte E, Hoffman W (2001) Opioidanalgetika in der Behandlung ambulanter Tumorpatienten 1993 bis 1996. Schmerz 2001 15: 26–32

    CAS  Google Scholar 

  158. Mutschier E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Arzneimittelwirkungen. Lehrbuch der Pharmakologie und Toxikologie, 8. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart

    Google Scholar 

  159. Nauck F (1994) Der Patient in der Finalphase. In: Klaschik E, Nauck F (Hrsg) Palliativmedizin Heute. Springer, Berlin, Heidelberg New York Tokio, pp 42–53

    Google Scholar 

  160. Nauck F, Klaschik E (2002) Schmerztherapie. Kompendium für Ausbildung und Praxis. Wisenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  161. Nauck F, Ostgathe C, Dickerson ED, Klaschik E (2002) Controlled-release hydromorphone: an alternative to morphine for cancer pain. The Pain Clinic, April 2002, 13–17

    Google Scholar 

  162. Newshan G (1998) Heat related toxicity with the fentanyl transdermal patch. J Pain Symptom Manage 16: 277–282

    PubMed  CAS  Google Scholar 

  163. Nitescu P, Sjoberg M, Appelgren L, Curelaru I (1995) Complications of intrathecal opioids and bupivacaine in the treatment of „refractory“ cancer pain. Clin J Pain 11: 45–62

    PubMed  CAS  Google Scholar 

  164. Ostgathe C, Nauck F, Klaschik E (2003) Schmerztherapie heute. Stand der Schmerztherapie in Deutschland. Anästhesiol Intensivmed Notfallmed Schmerzther 38: 312–320

    PubMed  CAS  Google Scholar 

  165. Patwardhan RV, Johnson RF, Hoyumpa A (1981) Normal metabolism of morphine in cirrhosis. Gastroenterology 81: 1006–1011

    PubMed  CAS  Google Scholar 

  166. Payne R, Thomas J, Prithivi Raj P (1992) Pain due to cancer — epidemiology and pharmacological approach. In: Prithivi Raj P (ed) Practical management of pain. Mosby Year Book, St. Louis

    Google Scholar 

  167. Peireira J, Lawlor P, Virgano A et al. (2001) Equianalgesicdose ratios for opioids: a critical review and proposals for long-term dosing. J Pain Symptom Manage 22: 672–687

    Google Scholar 

  168. Petzke F, Radbruch L, Sabatowski R et al. (2000) Slow-release tramadol for treatment of chronic malignant pain — an open multicenter trial. Support Care Cancer 9: 48–54

    Google Scholar 

  169. Philip J, Gold M, Milner A, Di lulio J, Miller B, Spruyt O (2006) A randomized, double-blind, crossover trial of the effect of oxygen on dyspnea in patients with advanced cancer. J Pain Symptom Manage 32(6): 541–550

    PubMed  CAS  Google Scholar 

  170. Portenoy RK (1996) Nontraditional analgesics in the management of cancer pain. In: Campbell JN (ed) Pain 1996 — An updated review. IASP Press, Seattle

    Google Scholar 

  171. Portenoy RK (1999a) Management of cancer pain. Lancet 353: 1695–1700

    PubMed  CAS  Google Scholar 

  172. Portenoy RK, Payne D, Coluzzi P et al. (1999b) Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79: 303–312

    PubMed  CAS  Google Scholar 

  173. Portenoy RK, Payne D, Jacobsen P (1999c) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81: 129–134

    PubMed  CAS  Google Scholar 

  174. Porter J, Jick H (1980) Addiction is rare in patients treated with narcotics (letter) N Engl J Med 302: 123

    PubMed  CAS  Google Scholar 

  175. Poyhia R, Seppala T, Olkkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33: 617–621

    PubMed  CAS  Google Scholar 

  176. Poyhia R, Vaino, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8: 63–67

    PubMed  CAS  Google Scholar 

  177. Radbruch L, Sabatowski R, Loick G et al. (2000) Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14: 111–119

    PubMed  CAS  Google Scholar 

  178. Radbruch L, Sabatowski R, Petzke F et al. (2001) Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med 15: 309–321

    PubMed  CAS  Google Scholar 

  179. Raffa RB, Friderichs E, Reimann W et al. (1992) Opioid and non-opioid components independently contribute to the mechanism of action in tramadol, an „atypical“ opioid analgesic. J Pharmacol Exp Ther 260: 275–285

    PubMed  CAS  Google Scholar 

  180. Regnard C (1987) Nausea and vomiting — a flow diagram. Palliat Med 1: 62–66

    Google Scholar 

  181. Regnard C, Hockley J (1995) Flow diagrams in advanced cancer and other diseases. Edward Arnold, London Boston Melbourne Auckland

    Google Scholar 

  182. Ripamonti C, Dickersen ED (2001) Strategies for the treatment of cancer pain in the new millennium. Drugs 61: 955–977

    PubMed  CAS  Google Scholar 

  183. Ripamonti C, Groff L, Brunelli O et al. (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16: 3216–3221

    PubMed  CAS  Google Scholar 

  184. Rose MA, Kam PC (2002) Gabapentin: pharmacology and its use in pain management. Anesthesia 57: 451–546

    CAS  Google Scholar 

  185. Saarialho-Kere U, Mattila MJ, Paloheimo M, Seppälä T (1987) Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol 33: 139–146

    PubMed  CAS  Google Scholar 

  186. Sabatowski R, Arens ER, Waap I, Radbruch L (2001) Tumorschmerztherapie in Deutschland. Ergebnisse und Analysen einer Befragung von Ärzten. Schmerz 15: 241–247

    PubMed  CAS  Google Scholar 

  187. Samuelsson H, Malmberg F, Eriksson M, Hedner T (1995) Outcomes of epidural morphine treatment in cancer pain: nine years of clinical experience. J Pain Symptom Manage 10/2: 105–112

    Google Scholar 

  188. Santiago-Palma J, Khojainova N, Kornick C et al. (2001) Intravenous methadone in the management of chronic cancer pain. Cancer 92: 1919–2019

    PubMed  CAS  Google Scholar 

  189. Schule-Hein K (1989) Palliative Strahlenbehandlung. In: Hankemeier U, Bowdler J, Zech D (Hrsg) Tumorschmerztherapie. Springer, Berlin Heildelberg NewYork Tokio, 102–123

    Google Scholar 

  190. Schuster CR (1989) Does treatment of cancer pain with narcotics produce junkies? In: Hill CS, Fields WS (eds) Drug treatment of cancer pain in a drug-oriented society. Raven, New York (Advances in pain research and therapy, vol 11, 1)

    Google Scholar 

  191. Schwabe U (2002) Qualität der Arzneimittelversorgung. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2002. Springer, Berlin Heidelberg New York Tokio, 832–852

    Google Scholar 

  192. Seiler KU, Jähnchen E, Trank D et al. (2001) Pharmacokinetics of tilidine in terminal renal failure. J Clin Pharmacol 41: 79–84

    PubMed  CAS  Google Scholar 

  193. Sindrup SH, Jensen TS (2001) Antidepressants in the treatment of neuropathic pain. In: Hansson PT, Fields RG, Hill RG, Marchetti P (eds) Neuropathic pain: pathophysiology and treatment. Progr Pain Res Manage Vol 21. IASP Press Seattle, 169–183

    Google Scholar 

  194. Smith MT, Watt JA (1990) Morphine-3-glucuronide — a potent antagonist of morphine analgesia. Life Sci 47: 57

    Google Scholar 

  195. Sonnenberg A, Koch TR (1989) Epidemiology of constipation in the United States. Dis Colon Rectum 1989; 32: 1–8

    PubMed  CAS  Google Scholar 

  196. Stein C, Cabot PJ, Schäfer M (1999) Peripheral opioid analgesia: mechanisms and clinical implications. In: Stein C (ed) Opioid in pain control. Cambridge University Press, Cambridge, 96–108

    Google Scholar 

  197. Stein WM (1996) Cancer pain in the elderly. In: Ferrell BR, Ferrel BA (eds) Pain in the elderly. IASP Press, Seattle

    Google Scholar 

  198. Stewart WF, Liberman JN, Sandier RS, Woods MS, Sternhagen A, Chee E, Lipton RB, Farup CE (1999) Epidemiology of constipation (EPOC) Study in the United States: Relation of clinical subtypes to socioeconomic features. Am J Gastroenterol 94: 3530–3539

    PubMed  CAS  Google Scholar 

  199. Striebel HW, Wessel A, Rieger A (1993) Intranasales Fentanyl zur Therapie akuter Schmerzspitzen bei Karzinompatienten. Eine Pilotstudie. Der Schmerz 7: 174–177

    CAS  Google Scholar 

  200. Strumpf M, Köhler A, Zenz M, Willweber-Strumpf A, Dertwinkel R, Donner B (1997) Opioide und Fahrtüchtigkeit. Schmerz 11: 233–240

    PubMed  CAS  Google Scholar 

  201. Strumpf M, Willweber-Strumpf A, Zenz M (2005) Tumorschmerz. Dtsch Ärztebl 102: 916–924

    Google Scholar 

  202. Talley NJ, Weaver AL, Zinsmeister AR (1993) Functional constipation and outlet delay. A population-based study. Gastroenterology 105: 781–790

    PubMed  CAS  Google Scholar 

  203. Taylor DR, Webster LR, Chun SY et al. (2007) Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perception and effect of treatment with oral transmucosal Fentanyl (OTFC® ACTIQ) Pain Med 8: 281–288

    PubMed  Google Scholar 

  204. Teuscher E (1979) Pharmazeutische Biologie — Alkaloide. Vieweg, Braunschweig

    Google Scholar 

  205. Teuscher E (1987) Biogene Gifte — Isocholin. G. Fischer, Stuttgart

    Google Scholar 

  206. Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anticonvulsants for neuropathic pain syndromes. Drugs 60: 1029–1052

    PubMed  CAS  Google Scholar 

  207. Tronnier V, Winkelmüller W (2001) Neurochirurgische Methoden. In: Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, S 373–382

    Google Scholar 

  208. Twycross R (1993) Symptom control: the problem areas. Palliat Med 7(Suppl 1): 1–8

    Google Scholar 

  209. Twycross R (1994) Pain relief in advanced cancer. Churchill Livingstone, Edinburgh London

    Google Scholar 

  210. Twycross R (1998) Opioid rotation. Does it have a role? Palliat Med 12: 60–61

    PubMed  CAS  Google Scholar 

  211. Twycross R (1999) Opioids. In: Wall PD, Melzack R (eds) Textbook of pain. 4th edition. Churchill Livingston, Edinburgh London, 1187–1214

    Google Scholar 

  212. Twycross R, Lack SA (1984) Symptom control in far advanced cancer. Pain relief. Pitman, London

    Google Scholar 

  213. Twycross RG (1979) Effect of cocaine in the Brompton cocktail. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG (eds) Advances in pain research and therapy, vol 3. Raven, New York, 927–932

    Google Scholar 

  214. Vainio A, Ollila J, Matikainen E, Rosenberg E, Kalso E (1995) Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 346: 667–670

    PubMed  CAS  Google Scholar 

  215. Vanderath TW, Ossipov MH, Lai J et al. (2001) Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain 92: 5–10

    Google Scholar 

  216. Walsh D, Nelson KA, Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 11(3): 137–143

    PubMed  Google Scholar 

  217. Walsh TD (1984) Opiates and respiratory function in advanced cancer. In: Zimmermann M, Drings P, Wagner G (eds) Pain in cancer patients. Springer, Berlin Heidelberg New York Tokyo, pp 115–117

    Google Scholar 

  218. Wanitschke R, Goerg KJ, Loew D (2003) Differential therapy of constipation a review. International Journal of Clinical Pharmacology and Therapeutics 41: 14–21

    PubMed  CAS  Google Scholar 

  219. Warfield CA (1993) Guidelines for routine use of controlled-release oral morphine sulphate tablets. Semin Oncol 20/2(Suppl 1): 36–47

    Google Scholar 

  220. Watson CPN, Babul N (1998) Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia. Neurology 50: 1837–1841

    PubMed  CAS  Google Scholar 

  221. WHO (1996) Cancer pain relief, with a guide to opioid availability. World Health Organisation, Geneva

    Google Scholar 

  222. WHO Expert Committee Report (1990) Cancer pain relief and palliative care. Technical report service no. 804. World Health Organisation, Geneva

    Google Scholar 

  223. Willweber-Strumpf A, Zenz M, Tryba M (1995) Leitlinien zur Therapie chronischer Schmerzen mit Opioiden. Anaesthesist 44: 719–723

    PubMed  CAS  Google Scholar 

  224. Winkelmüller W (1992) Neurostimulation: Einführung in die Thematik. Der Schmerz 6(Suppl 1): 26

    Google Scholar 

  225. Yaksh TL (1996) Intrathecal and epidural opiates: A review. In: Campbell JN (ed) Pain 1996 — An updated review. IASP Press, Seattle, 381–393

    Google Scholar 

  226. Zech D, Grond S, Lehmann KA (1995) Transdermales Fentanyl zur Behandlung von Tumorschmerzen. Dtsch Ärztebl 92: 2554–2561

    Google Scholar 

  227. Zech D, Schug SA, Grond S (1992) Therapiekompendium Tumorschmerz und Symptomkontrolle. Perimed-Spitta, Erlangen

    Google Scholar 

  228. Zenz M (1993) Taschenbuch der Schmerztherapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  229. Zenz M (2001 ) Zu schön, um wahr zu sein. Arzneimittelverordnungs-Report bescheinigt Deutschland Vollversorgung beim Tumorschmerz. Schmerz 15:409–410

    Google Scholar 

  230. Zenz M, Jurna I (1993) Lehrbuch der Schmerztherapie. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

    Google Scholar 

  231. Zenz M, Jurna I (Hrsg) (2001) Lehrbuch der Schmerztherapie, 2. Auflage. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart

    Google Scholar 

  232. Zenz M, Zenz T, Tryba M, Strumpf M (1995) Severe undertreatment of cancer pain: a 3-year survey of the German situation. J Pain Symptom Manage 10(3): 187–191

    PubMed  CAS  Google Scholar 

  233. Zernikow B, Hechler T (2008) Schmerztherapie bei Kindern und Jugendlichen. Deutsches Ärzteblatt 105(28-29): 511–521

    Google Scholar 

  234. Zöllner C, Schäfer M (2008) Opioide in der Anästhesie. Anaesthesist 57(7): 729–742

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oberdorf 53, 53347, Alfter

    Prof. em. Dr. med. Eberhard Klaschik

Authors
  1. Prof. em. Dr. med. Eberhard Klaschik
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. WürdeCenter Bergen Rote Kreuz Pflegeheim, N-5043, Bergen, Norwegen

    Stein Husebø

  2. Oberdorf 53, 53347, Alfter

    E. Klaschik

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Klaschik, E. (2009). Schmerztherapie und Symptomkontrolle in der Palliativmedizin. In: Husebø, S., Klaschik, E. (eds) Palliativmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01549-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01549-6_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01548-9

  • Online ISBN: 978-3-642-01549-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation